102.53
4.46 (4.55%)
| Previous Close | 98.07 |
| Open | 98.29 |
| Volume | 597,852 |
| Avg. Volume (3M) | 763,563 |
| Market Cap | 6,842,447,872 |
| Price / Sales | 32.03 |
| Price / Book | 45.92 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Profit Margin | -123.28% |
| Operating Margin (TTM) | -143.73% |
| Diluted EPS (TTM) | -2.80 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 69.65% |
| Current Ratio (MRQ) | 3.30 |
| Operating Cash Flow (TTM) | -113.49 M |
| Levered Free Cash Flow (TTM) | -96.71 M |
| Return on Assets (TTM) | -51.33% |
| Return on Equity (TTM) | -150.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Rhythm Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 103.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 176.00 (Citizens, 71.66%) | Buy |
| Median | 141.50 (38.01%) | |
| Low | 110.00 (HC Wainwright & Co., 7.29%) | Buy |
| Average | 143.25 (39.72%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 97.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 02 Mar 2026 | 140.00 (36.55%) | Buy | 94.94 |
| 12 Dec 2025 | 141.00 (37.52%) | Buy | 113.56 | |
| HC Wainwright & Co. | 02 Mar 2026 | 110.00 (7.29%) | Buy | 94.94 |
| 20 Jan 2026 | 125.00 (21.92%) | Buy | 102.59 | |
| Citizens | 27 Feb 2026 | 176.00 (71.66%) | Buy | 92.73 |
| 12 Dec 2025 | 167.00 (62.88%) | Buy | 113.56 | |
| Guggenheim | 27 Feb 2026 | 143.00 (39.47%) | Buy | 92.73 |
| 17 Dec 2025 | 140.00 (36.55%) | Buy | 111.86 | |
| Wells Fargo | 27 Feb 2026 | 136.00 (32.64%) | Buy | 92.73 |
| 20 Jan 2026 | 145.00 (41.42%) | Buy | 102.59 | |
| Needham | 26 Feb 2026 | 139.00 (35.57%) | Buy | 98.07 |
| 09 Jan 2026 | 148.00 (44.35%) | Buy | 101.02 | |
| RBC Capital | 19 Feb 2026 | 145.00 (41.42%) | Buy | 103.16 |
| Goldman Sachs | 12 Dec 2025 | 157.00 (53.13%) | Buy | 113.56 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |